Icon (NASDAQ:ICLR) Shares Up 10.2% – What’s Next?

Shares of Icon Plc (NASDAQ:ICLR) rose 10.2% during mid-day trading on Thursday . The company traded as high as $128.06 and last traded at $130.54. Approximately 546,197 shares were traded during trading, a decline of 65% from the average daily volume of 1,567,196 shares. The stock had previously closed at $118.45.

Analysts Set New Price Targets

ICLR has been the subject of a number of research analyst reports. TD Cowen upgraded shares of Icon from a “hold” rating to a “buy” rating and lowered their price objective for the stock from $183.00 to $120.00 in a research report on Wednesday, February 18th. BMO Capital Markets upgraded shares of Icon from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $100.00 to $130.00 in a research report on Thursday, March 26th. Citigroup dropped their price target on Icon from $200.00 to $120.00 and set a “neutral” rating for the company in a research note on Wednesday, March 11th. Barclays dropped their price target on Icon from $200.00 to $120.00 and set an “equal weight” rating for the company in a research note on Monday, March 9th. Finally, Leerink Partners set a $125.00 price target on Icon in a research note on Monday, May 4th. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, Icon has an average rating of “Hold” and an average price target of $147.67.

Icon Stock Performance

The firm has a market capitalization of $11.08 billion, a P/E ratio of 18.59, a price-to-earnings-growth ratio of 2.97 and a beta of 1.23. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. The company has a 50-day moving average of $111.55 and a 200-day moving average of $141.66.

Icon (NASDAQ:ICLR) last announced its earnings results on Wednesday, May 27th. The medical research company reported $2.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.14 by ($0.62). The company had revenue of $2.11 billion for the quarter, compared to the consensus estimate of $1.98 billion. Icon had a return on equity of 10.58% and a net margin of 7.40%.The firm’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same period in the prior year, the business earned $3.43 earnings per share. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. On average, equities analysts anticipate that Icon Plc will post 11.53 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Icon

Hedge funds have recently bought and sold shares of the company. Sanctuary Advisors LLC raised its position in shares of Icon by 1.1% in the 4th quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock worth $899,000 after acquiring an additional 56 shares in the last quarter. Geneos Wealth Management Inc. raised its position in shares of Icon by 11.5% in the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after acquiring an additional 56 shares in the last quarter. New Wave Wealth Advisors LLC raised its position in shares of Icon by 5.1% in the 4th quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock worth $270,000 after acquiring an additional 72 shares in the last quarter. Signaturefd LLC raised its position in shares of Icon by 12.6% in the 4th quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock worth $117,000 after acquiring an additional 72 shares in the last quarter. Finally, Janney Montgomery Scott LLC raised its position in shares of Icon by 0.4% in the 4th quarter. Janney Montgomery Scott LLC now owns 23,942 shares of the medical research company’s stock worth $4,363,000 after acquiring an additional 93 shares in the last quarter. Institutional investors own 95.61% of the company’s stock.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.